Evidence map›Paper›PMID 30105677›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2018

Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It.

Sjors Klompmaker, Ugo Boggi, Thilo Hackert, Roberto Salvia, Matthew Weiss, Hiroki Yamaue, Herbert J Zeh, Marc G Besselink

Open access · hybridAbstract read
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Distal and Total Pancreatectomy With En Bloc Celiac Axis Resection for Pancreatic Cancer at a High-Volume Center.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Neoadjuvant therapy for pancreatic cancer.Nature reviews. Clinical oncology · 2023
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 5 countries.

Sjors KlompmakerDepartment of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.ORCID 0000-0002-1161-7845
Ugo BoggiDivision of General and Transplant Surgery, University of Pisa, Pisa, Italy.
Thilo HackertDepartment of General, Visceral and Transplantation Surgery, Heidelberg University, Heidelberg, Germany.
Roberto SalviaDepartment of Surgery, University of Verona, Verona, Italy.
Matthew WeissDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Hiroki YamaueSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Herbert J ZehDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
Marc G BesselinkDepartment of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands. m.g.besselink@amc.nl.
Amsterdam University Medical Centers · NLHeidelberg University · DEJohns Hopkins Hospital · USSouthwestern Medical Center · USUniversity of Pisa · ITUniversity of Verona · ITWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 30% of all pancreatic cancer patients have locally advanced (AJCC stage 3) disease. A sub-group of these patients-where the cancer only involves the celiac axis-may benefit from distal pancreatectomy with celiac axis resection (DP-CAR). Previous studies have shown that DP-CAR offers a survival benefit to a selected group of patients with otherwise unresectable pancreatic cancer, when performed by experienced pancreatic cancer treatment teams at high-volume centers. This article proposes a standardized approach to DP-CAR, including routine neoadjuvant (FOLFIRINOX) chemotherapy. This approach to selecting patients and performing DP-CAR has the potential to improve short-term outcomes and overall survival in selected patients, but it should be reserved for high-volume centers.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCeliac ArteryChemotherapy, AdjuvantFluorouracilHumansIrinotecanLeucovorinNeoadjuvant TherapyNeoplasm StagingOxaliplatinPancreatectomyPancreatic NeoplasmsPatient SelectionPostoperative ComplicationsRetrospective StudiesSurvival RateFluorouracilfolfirinoxIrinotecanLeucovorinOxaliplatinApplebyCancerDP-CARHigh volumeIschemiaMorbidityMortalityPancreasPancreas surgeryPancreatic cancerPancreatic fistulaSurvivalTechnique

Identifiers

PMID30105677
PMCPMC6153684
OpenAlexW2886506441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.